LoginSignup
CLV

Clinuvel Pharmaceuticals ADR Stock

StockStock
ISIN: US1887691038
Ticker: CLVLY
US1887691038
CLVLY

Price

Historical dividends and forecast

All dividend data

Clinuvel Pharmaceuticals ADR has so far distributed $0.034 in 2024. The next dividend will be paid on 30.09.2025

$0.0262

CHART BY

Frequently asked questions

What is Clinuvel Pharmaceuticals ADR's market capitalization?

The market capitalization of Clinuvel Pharmaceuticals ADR is $436.88M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Clinuvel Pharmaceuticals ADR's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Clinuvel Pharmaceuticals ADR is 19.29. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Clinuvel Pharmaceuticals ADR?

Clinuvel Pharmaceuticals ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.452. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Clinuvel Pharmaceuticals ADR's stock?

Currently, 4 analysts cover Clinuvel Pharmaceuticals ADR's stock, with a consensus target price of $17.04. Analyst ratings provide insights into the stock's expected performance.

What is Clinuvel Pharmaceuticals ADR's revenue over the trailing twelve months?

Over the trailing twelve months, Clinuvel Pharmaceuticals ADR reported a revenue of $61.60M.

What is the EBITDA for Clinuvel Pharmaceuticals ADR?

Clinuvel Pharmaceuticals ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $37.55M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Clinuvel Pharmaceuticals ADR?

Clinuvel Pharmaceuticals ADR has a free cash flow of $18.71M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Clinuvel Pharmaceuticals ADR's stock?

The 5-year beta for Clinuvel Pharmaceuticals ADR is 0.66. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Clinuvel Pharmaceuticals ADR have, and what sector and industry does it belong to?

Clinuvel Pharmaceuticals ADR employs approximately 16 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Clinuvel Pharmaceuticals ADR's shares?

The free float of Clinuvel Pharmaceuticals ADR is 41.44M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $436.88M

5Y beta

 0.66

EPS (TTM)

 $0.452

Free Float

 41.44M

P/E ratio (TTM)

 19.29

Revenue (TTM)

 $61.60M

EBITDA (TTM)

 $37.55M

Free Cashflow (TTM)

 $18.71M

Pricing

52W span
$7.927$11.43

Analyst Ratings

The price target is $17.04 and the stock is covered by 4 analysts.

Buy

4

Hold

0

Sell

0

Information

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).

16

Biotechnology & Drugs

Health Care

Identifier

ISIN

US1887691038

Primary Ticker

CLVLY
Join the conversation
Sign upLogin